[Legal framework for the use of autologous blood and other alternatives to allogenic transfusion].
Muñoz
Manuel
M
GIEMSA, Medicina Transfusional, Facultad de Medicina, Universidad de Málaga, Málaga, España. mmunoz@uma.es
García-Erce
José Antonio
JA
Campos
Arturo
A
Fernando Barrios
Luis
L
D007611:Aprotinin / Q000008:administration & dosage; D001803:Blood Transfusion / Q000941:ethics / Q000331:legislation & jurisprudence* / Q000592:standards; D001804:Blood Transfusion, Autologous / Q000331:legislation & jurisprudence*; D002986:Clinical Trials as Topic; D003029:Coagulants / Q000008:administration & dosage; D004921:Erythropoietin / Q000008:administration & dosage; D015942:Factor VIIa / Q000008:administration & dosage; D006438:Hemodilution; D006490:Hemostatics / Q000008:administration & dosage; D006801:Humans; D007258:Informed Consent; D011300:Preoperative Care; D013030:Spain
D003029:Coagulants; D006490:Hemostatics; D004921:Erythropoietin; D007611:Aprotinin; D015942:Factor VIIa